Therefore, we investigated whether early treatment with an anti-HMGB1 blocking antibody could (1) improve the clinical manifestations of dry eye, (2) decrease the responses of autoreactive B cells or Th17 cells, and (3) affect changes in ILC3s that might be involved in modification of epithelial wound healing in NOD.B10.H2b mice. This evidence concerns the gene HMGB1 and dry eye syndrome.